| APC | APC regulator of WNT signaling pathway |
| ATR | ataxia telangiectasia and RAd3-related kinase |
| BCDX2 complex | RAD51 paralogs (RAD51B, RAD51C, RAD51D) and XRCC2 |
| BMPR1A | bone morphogenetic protein receptor type 1A |
| BRAF | B-Raf proto-oncogene, serine/threonine kinase |
| BRCA | BRCA1 DNA repair associated (alias FANCS) |
| BRCA2 | BRCA2 DNA repair associated (alias FANCD, FANCD1) |
| BRIP1 | BRCA1 interacting helicase 1 (alias FANCJ) |
| CHK1 | checkpoint kinase1 |
| CNV | copy number variation |
| CRC | colorectal cancer |
| dNTP | deoxyribonucleoside triphosphate |
| DSB | double-strand break |
| EOCRC | early-onset CRC |
| ERCC1 | ERCC excision repair 1, endonuclease catalytic subunit |
| ERCC4 | ERCC excision repair 4, endonuclease catalytic subunit (alias FANCQ) |
| FA | Fanconi anemia |
| FAAP | RNA 2′,3′-cyclic phosphate and 5′-OH ligase |
| FAAP100 | FA core complex associated protein 100 |
| FAAP20 | FA core complex associated protein 20 |
| FAAP24 | FA core complex associated protein 24 |
| FAN1 | FANCD2 and FANCI associated nuclease 1 |
| FANC | FA complementation group |
| FANCA | FA complementation group A |
| FANCB | FA complementation group B |
| FANCC | FA complementation group C |
| FANCD1 | BRCA2 DNA repair associated (official symbol BRCA2) |
| FANCD2 | FA complementation group D2 |
| FANCE | FA complementation group E |
| FANCF | FA complementation group F |
| FANCG | FA complementation group G (alias XRCC9) |
| FANCI | FA complementation group I |
| FANCJ | BRCA1 interacting helicase 1 (official symbol BRIP1) |
| FANCL | FA complementation group L |
| FANCM | FA complementation group M |
| FANCN | partner and localizer of BRCA2 (official symbol PALB2) |
| FANCO | RAD51 paralog C (official symbol RAD51C) |
| FANCP | SLX4 structure-specific endonuclease subunit |
| FANCQ | ERCC excision repair 4, endonuclease catalytic subunit (official symbol ERCC4) |
| FANCR | RAD51 recombinase (official symbol RAD51) |
| FANCS | BRCA1 DNA repair associated (official symbol BRCA) |
| FANCT | FA complementation group T/Ubiquitin Conjugating Enzyme E2 T (official symbol UBE2T) |
| FANCU | X-ray repair cross complementing 2 (official symbol XRCC2) |
| FANCV | mitotic arrest deficient 2 like 2 (official symbol: MAD2L2; alias REV7) |
| FANCW | ring finger and WD repeat domain 3 (official symbol RFWD3) |
| FCCTX | familial CRC type X |
| FOLFIRI | fluorouracil/leucovorin, irinotecan |
| FOLFOX | fluorouracil/leucovorin, oxaliplatin |
| G4 | G-quadruplex |
| GEO | Gene Expression Omnibus |
| HR | homologous recombination |
| HRR | homologous recombinational repair |
| ICL | inter-strand crosslink |
| ID2 complex | FANCI-FANCD2 |
| KRAS | Kirsten RAS proto-oncogene |
| LARC | locally advanced rectal cancer |
| mCRC | metastatic CRC |
| MEK1 | mitogen-activated protein kinase kinase 1 (official symbol MAP2K1) |
| MEK2 | mitogen-activated protein kinase kinase 2 (official symbol MAP2K2) |
| MHF1 | centromere protein S (official symbol CENPS) |
| MHF2 | centromere protein X (official symbol CENPX) |
| MLH1 | mutL homolog 1 |
| MLH2 | PMS1 homolog 1, mismatch repair system component (official symbol PMS1) |
| MMR | mismatch repair, |
| MRN complex | MRE11-RAD50-NBS proteins |
| MSH2 | mutS homolog 2 |
| MSH6 | mutS homolog 6 |
| MSI | microsatellite instability |
| MSS | microsatellite stability |
| MUTYH | mutY DNA glycosylase |
| NCI GDC | National Cancer Institute-Genomic Data Commons |
| NER | nucleotide excision repair |
| NGS | next-generation sequencing; |
| NHEJ | non-homologous end joining |
| NTHL | nth like DNA glycosylase |
| PALB2 | partner and localizer of BRCA2 (alias FANCN) |
| PARP1 | poly (ADP-ribose) polymerase 1 |
| PARPi | PARP inhibitor |
| PFS | progression-free survival |
| PMS2 | PMS1 homolog 2, mismatch repair system component |
| POLD1 | DNA polymerase delta 1, catalytic subunit |
| POLE | DNA polymerase epsilon, catalytic subunit |
| POLQ | DNA polymerase theta |
| PPAP | polymerase proofreading–associated polyposis |
| PPI | protein–protein interaction |
| PTEN | phosphatase and tensin homolog |
| PV | pathogenic variation |
| RAD51 | RAD51 recombinase (alias FANCR) |
| RAD51B | RAD51 paralog B |
| RAD51C | RAD51 paralog C (alias FANCO) |
| RAD51D | RAD51 paralog D |
| REV1 | REV1 DNA directed polymerase |
| REV7 | mitotic arrest deficient 2 like 2 (official symbol: MAD2L2; alias FANCV) |
| RFWD3 | ring finger and WD repeat domain 3 (alias FANCW) |
| RNaseH | ribonuclease H |
| SMAD4 | SMAD family member 4 |
| ssDNA | single-strand DNA |
| STK11 | serine/threonine kinase 11 |
| TLS | translesion DNA synthesis |
| TMEJ | polymerase theta-mediated end joining |
| TMS | telomestatin |
| TNM | tumor (lymph) node metastasis staging |
| TP53 | tumor protein p53 |
| UBE2T | Ubiquitin Conjugating Enzyme E2 T (alias FANCT) |
| VEGF | Vascular endothelial growth factor |
| WES | whole-exome sequencing |
| XRCC2 | X-ray repair cross complementing 2 (alias FANCU) |